Skip to main content

The OncoLens Research Network (ORN)

Life Science companies and Clinical Research Organizations (CROs) get to work with the cancer centers within the OncoLens research network.
3M+ integrated patient records
90% community focused
Phase 1 to 3 capable
Commercial, RWE and Clinical trial teams engage the OncoLens Research Network (ORN) for insights into community and academic based care settings, to establish trials, or to drive physician education. Through the ORN, not only can you understand what is going on, but you also get to engage centers to work collectively towards a shared goal.  Contact Us to learn more.
Access patients within the community and not just academic settings:
  • Identify hard-to-find patients with specific mutations or misdiagnosis for hyper-targeted therapies
  • Address issues such as gaps in care and not just identify them
  • Identify sites with the infrastructure, volume and capability to take on your programs
  • Gather real-time data driven insights, often in collaboration with centers, to make sure you can address the problem at hand

OncoLens Clinical Trials

Services offered to clinical development, clinical operations and clinical research organizations range from the delivery of data and insights to site identification and patient screening.
OncoLens offers the ability to engage with a diverse and fast growing network of cancer centers, bringing both community and academic representation to support your research initiatives. Our ability to run data driven feasibility analysis prevents wasted spend and effort resulting from the wrong centers for your trials. Our relationships with the centers and PIs enable quick engagement and validation that the site is right for your trial. OncoLens continues to support your trials through our AI driven patient screening tools to deliver rapid accruals.
Contact us to learn more.
Read case studies here

OncoLens Precision Oncology

With biomarker testing becoming even more critical to identifying the right treatment for a patient, OncoLens provides a variety of solutions to help close the gap in appropriate testing.
OncoLens Patient ID sends alerts to care teams when patients have missed appropriate germline or somatic testing. OncoLens Quality Improvement Initiatives help to engage care teams and centers in larger scale workflow change to close gaps in care.
Read more case studies here

OncoLens Real World Data and Insights

Through our partnership with cancer centers and access to clinical and lab data, OncoLens can deliver unprecedented insight into oncology care.
Our AI models extract information from unstructured data including pdfs and clinical progress notes and pull together the answers to the questions you are looking to find. Our close relationship with our centers enable us to go above and beyond to close the gaps in the data you already have.
Learn more about how we can deliver:
  • Patient journey reports
  • Biomarker testing analysis
  • Competitive assessments
  • Community-based decision making
Read case studies here

OncoLens Market Launch Support

If you are looking to drive education on newly approved treatments or close gaps in existing practices, OncoLens can help.
Through our close relationships with our cancer centers, OncoLens provides the ability to engage with care teams through our digital platforms, educational campaigns and quality improvement initiatives.
Read more case studies here

OncoLens Rare Disease

The timeliness of finding patients eligible for your targeted therapy
is critical in the world of rare diseases.
OncoLens enables the identification of these patients within its network, sending alerts to cancer care teams so they can take appropriate action with the opportunity to direct care towards a potentially life-saving therapy.
Contact us to find out more on how to engage with our cancer centers.
Read case studies here

Accelerate the future of oncology with connected insights & intelligent collaboration

Schedule a demo and discover how OncoLens can help drive impact across care and research.
Contact Us
In Precision Medicine, using platforms like OncoLens in partnership with alliance stakeholders, allows for quality improvement projects to prove the impact of innovation on improved patient care, through real time data and clinical team engagement.
Director of Precision Oncology, Large Pharmaceutical

Frequently Asked Questions

How does OncoLens provide actionable insights to inform real‑world evidence (RWE) and optimize trial design?
OncoLens delivers real-world insights into oncology care by partnering with cancer centers and accessing clinical and lab data. Our AI technology extracts key data from unstructured sources like clinical notes and PDFs, providing Life Science teams with treatment pattern analysis, biomarker testing trends, and care gap identification. These insights help optimize clinical trial design, support real-world evidence (RWE) generation, and power projects like patient journey reports and competitive assessments.
How does OncoLens accelerate patient accrual in clinical trials with smarter screening strategies?
OncoLens accelerates clinical trial enrollment by partnering with cancer centers to deploy AI-driven patient screening. Our platform continuously analyzes EMR data andin real-time identifies eligible patients based on trial I/E criteria, increasing match accuracy, reducing manual workload, and improving accrual timelines.
How does OncoLens ensure timely germline and somatic biomarker testing for precision oncology treatments?
OncoLens monitors biomarker testing performance across partner cancer centers, tracking completion rates and turnaround times. Life Science teams gain real-time visibility into delays and disparities, helping ensure timely access to critical testing and enhancing eligibility for targeted therapies.
How can OncoLens help Life Science teams identify and engage rare disease patient cohorts more efficiently?
OncoLens uses AI and natural language processing to surface patients with rare cancers or biomarker-defined subtypes from structured and unstructured EMR data. This enables Life Science sponsors to identify and collaborate with cancer centers treating hard-to-reach or underrepresented patient populations.
What quality improvement frameworks does OncoLens offer to close gaps in testing workflows and care delivery?
OncoLens enables Life Science teams to support quality improvement (QI) initiatives by providing insights into testing rates, treatment adherence, and demographic trends. The platform empowers collaborative efforts with cancer centers to address care gaps and standardize workflows.
How can OncoLens’s digital engagement tools educate oncology care teams on newly approved treatments?
OncoLens offers in-platform digital engagement capabilities that allow Life Science companies to deliver clinical education, guideline updates, and new treatment information directly to oncology care teams. This improves awareness and adoption of approved therapies in real-world settings.
How does OncoLens help streamline site engagement and validation to ensure clinical trial success?
OncoLens improves clinical trial startups by giving Life Science teams access to performance metrics from partner cancer centers. These insights include protocol alignment, patient volumes, and operational readiness, helping streamline site engagement and validation.
How can OncoLens’s research network support the identification of high quality clinical trial sites and investigator networks?
OncoLens connects Life Science companies with a vetted research network of community and academic cancer centers. With access to investigator profiles, patient population data, and trial infrastructure, sponsors can efficiently identify high-quality clinical trial sites.
How does OncoLens’s real time data access and insights contribute to quicker decision‑making throughout the trial lifecycle?
OncoLens offers real-time access to clinical, operational, and trial performance data across partner sites. Life Science teams use these insights to make informed, agile decisions at every phase of the clinical trial process, from feasibility to closeout.
How can OncoLens help connect my company with the right cancer centers for clinical trials?
OncoLens matches trial protocols to the clinical capabilities, patient demographics, and operational strengths of its cancer center partners. This ensures faster alignment between Life Science sponsors and the most appropriate trial sites.
What types of clinical trials and research projects can OncoLens support?
OncoLens supports a wide range of oncology research initiatives including interventional trials, observational studies, biomarker-driven studies, real-world evidence (RWE) projects, and collaborative quality improvement programs.
How does OncoLens ensure effective collaboration between Life Science companies and cancer centers?
OncoLens provides a white-glove partnership experience from start to finish. Our shared platform enables seamless communication, project oversight, and access to clinical insights. This high-touch support model strengthens alignment between Life Science sponsors and cancer centers, ensuring clarity, reducing friction, and accelerating trial success.
How can OncoLens help Life Science companies navigate the complexities of launching quality improvement projects in cancer care?
OncoLens enables Life Science companies to launch and manage oncology quality improvement initiatives in close collaboration with cancer centers. Acting as an active liaison, our team facilitates communication, ensures goal alignment, and supports execution from feasibility to closeout. The platform powers data access, tracks progress, and measures outcomes to ensure each project delivers meaningful, measurable results.